Mersana Therapeutics Inc (NASDAQ:MRSN) – Leerink Swann issued their Q1 2019 earnings per share (EPS) estimates for Mersana Therapeutics in a research note issued to investors on Thursday, January 24th, according to Zacks Investment Research. Leerink Swann analyst J. Chang expects that the company will earn ($0.79) per share for the quarter. Leerink Swann has a “Outperform” rating on the stock. Leerink Swann also issued estimates for Mersana Therapeutics’ Q2 2019 earnings at ($0.80) EPS, Q3 2019 earnings at ($0.82) EPS, FY2019 earnings at ($2.96) EPS and FY2020 earnings at ($2.32) EPS.
Several other equities analysts have also recently commented on the stock. HC Wainwright set a $23.00 price target on shares of Mersana Therapeutics and gave the company a “buy” rating in a report on Wednesday, November 28th. ValuEngine cut shares of Mersana Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $25.33.
NASDAQ:MRSN traded down $0.02 during trading hours on Monday, hitting $6.71. 384,909 shares of the stock traded hands, compared to its average volume of 115,809. Mersana Therapeutics has a fifty-two week low of $2.85 and a fifty-two week high of $23.96. The company has a market cap of $156.02 million, a P/E ratio of -2.08 and a beta of 1.58.
A number of large investors have recently modified their holdings of the stock. Bank of New York Mellon Corp boosted its holdings in Mersana Therapeutics by 27.4% during the second quarter. Bank of New York Mellon Corp now owns 31,615 shares of the company’s stock valued at $564,000 after acquiring an additional 6,804 shares during the period. Schwab Charles Investment Management Inc. boosted its holdings in Mersana Therapeutics by 20.7% during the second quarter. Schwab Charles Investment Management Inc. now owns 24,500 shares of the company’s stock valued at $438,000 after acquiring an additional 4,200 shares during the period. BlackRock Inc. boosted its holdings in Mersana Therapeutics by 23.0% during the second quarter. BlackRock Inc. now owns 1,006,357 shares of the company’s stock valued at $17,973,000 after acquiring an additional 188,353 shares during the period. Millennium Management LLC bought a new stake in Mersana Therapeutics during the second quarter valued at about $2,198,000. Finally, Northern Trust Corp boosted its holdings in Mersana Therapeutics by 13.9% during the second quarter. Northern Trust Corp now owns 127,162 shares of the company’s stock valued at $2,271,000 after acquiring an additional 15,493 shares during the period. Hedge funds and other institutional investors own 85.85% of the company’s stock.
About Mersana Therapeutics
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of oncology therapeutics in the United States and Canada. The company develops Dolaflexin, an antibody drug conjugate (ADC) platform designed to enhance the potency and efficacy of ADCs while simultaneously enhancing the safety and tolerability.
Read More: What is the NASDAQ?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.